RT Journal Article
SR Electronic
T1 Longitudinal profiles of plasma gelsolin, cytokines and antibody expression predict COVID-19 severity and hospitalization outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.01.22275882
DO 10.1101/2022.06.01.22275882
A1 Asare-Werehene, Meshach
A1 McGuinty, Michaeline
A1 Vranjkovic, Agatha
A1 Galipeau, Yannick
A1 Cowan, Juthaporn
A1 Cameron, Bill
A1 Cooper, Curtis L.
A1 Langlois, Marc-André
A1 Crawley, Angela M.
A1 Tsang, Benjamin K.
YR 2022
UL http://medrxiv.org/content/early/2022/06/02/2022.06.01.22275882.abstract
AB Background Prognostic markers for COVID-19 disease outcome are currently lacking. Plasma gelsolin (pGSN) is an actin-binding protein and an innate immune marker involved in disease pathogenesis and viral infections. Here, we demonstrate the utility of pGSN as a prognostic marker for COVID-19 disease outcome; a test performance that is significantly improved when combined with cytokines and antibodies compared to other conventional markers such as CRP and ferritin.Methods Blood samples were longitudinally collected from hospitalized COVID-19 patients as well as COVID-19 negative controls and the levels of pGSN in μg/mL, cytokines and anti-SARS-CoV-2 spike protein antibodies assayed. Mean±SEM values were correlated with clinical parameters to develop a prognostic platform.Results pGSN levels were significantly reduced in COVID-19 patients compared to healthy individuals. Additionally, pGSN levels combined with plasma IL-6, IP-10 and M-CSF significantly distinguished COVID-19 patients from healthy individuals. While pGSN and anti-spike IgG titers together strongly predict COVID-19 severity and death, the combination of pGSN and IL-6 was a significant predictor of milder disease and favorable outcomes.Conclusion Taken together, these findings suggest that multi-parameter analysis of pGSN, cytokines and antibodies could predict COVID-19 hospitalization outcomes with greater certainty compared with conventional clinical laboratory markers such as CRP and ferritin. This research will inform and improve clinical management and health system interventions in response to SARS-CoV-2 infection.Trial Registration N/AFunding The Ottawa Hospital Department of Medicine - Special Pandemic Agile Research CompetitionCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from The Ottawa Hospital Department of Medicine - Special Pandemic Agile Research CompetitionAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ottawa Health Science Network Research Ethics Board (OHSNREB; Protocol# 20200200-01H) and conducted in accordance with the appropriate guidelines. Written informed consent was obtained from all subjects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.